Evidence map›Paper›PMID 33593826›Full record

ArticleJournal for immunotherapy of cancer2021

Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model.

Jing Wen, Lan Wang, Jie Ren, Emiko Kranz, Shilin Chen, Di Wu, Toshio Kanazawa, Irvin Chen, Yunfeng Lu, Masakazu Kamata

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal for immunotherapy of cancer, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. A proimmunotoxin nanodrug targeting AIDS-associated non-Hodgkin lymphoma.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Jing Wen *Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Lan Wang *Department of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Jie RenDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, USA.
Emiko KranzDepartment of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Shilin ChenDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, USA.
Di WuDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, USA.
Toshio KanazawaDepartment of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Irvin ChenDepartment of Microbiology, Immunology and Molecular Genetics, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
Yunfeng LuDepartment of Chemical and Biomolecular Engineering, University of California Los Angeles, Los Angeles, California, USA.
Masakazu KamataMicrobiology, University of Alabama at Birmingham School of Arts and Humanities, Birmingham, Alabama, USA masa3k@uab.edu.ORCID 0000-0003-0323-3742
University of California, Los Angeles · USUniversity of Alabama at Birmingham · US

Funding

Nanodelivery platform for antibody drugs targeting NHLR01CA232015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KAMATA, MASAKAZU · 2018 to 2022
$2.5M
Targeting delivery of mAbs to CNS metastasesR01CA253215 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WEN, JING · 2020 to 2024
$1.7M
Gene-Engineered Stem Cell Memory T-Cells With Anti-HIV Chimeric Antigen ReceptorsR01AI110200 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KAMATA, MASAKAZU · 2016 to 2019
$1.5M
NCI NIH HHS R01 CA232015NCI NIH HHS R01 CA253215NIAID NIH HHS R01 AI110200
6 · The paper itself

Abstract

backgroundDespite the numerous applications of monoclonal antibodies (mAbs) in cancer therapeutics, animal models available to test the therapeutic efficacy of new mAbs are limited. NOD.Cg-

methodsWe have developed a humanized mouse model using a novel NSG strain, NOD.Cg

resultsAs expected, xenografted humanized NSG

conclusionsThese results indicate that NSG

Indexed as

AnimalsBurkitt LymphomaCell Line, TumorChemokines, CXCHumansMaleMiceMice, Inbred NODMice, SCIDMice, TransgenicNanocapsulesNeoplasm MetastasisRituximabTreatment OutcomeXenograft Model Antitumor AssaysChemokines, CXCCXCL3 protein, humanNanocapsulesRituximabantibodiescellularimmunityimmunotherapyneoplasmvaccination

Identifiers

PMID33593826
PMCPMC7888328
OpenAlexW3132059021

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.